Drug-induced side effects affecting the gastrointestinal tract

With the ever-growing armamentarium of pharmacological agents, the gastrointestinal drug-induced side effects of dyspepsia, nausea, vomiting, diarrhoea and constipation are increasingly seen. They are often self-limiting and without serious sequelae, but of greater concern is drug-induced mucosal ulceration that can manifest as gastrointestinal haemorrhage, stricture and perforation. These complications are mainly attributable to NSAIDs and aspirin, which can injure the mucosa anywhere along the gastrointestinal tract. These iatrogenic serious side effects can be reduced with co-prescription of a proton pump inhibitor, substitution of a COX-2 inhibitor and eradication of Helicobacter pylori when the bacterium is present. Other recognised gastrointestinal complications include small intestinal diaphragm, microscopic colitis, a range of hepatotoxic effects and pancreatitis. The introduction of new classes of drugs has resulted in new adverse effects that require consideration in patients presenting with gastroenterological symptoms. These include pill oesophagitis from bisphosphonates and ischaemic colitis relating to serotonin antagonists. Here, the authors review the literature on drug-induced complications of the gastrointestinal tract and present the pertinent management issues relevant to clinical practice.

[1]  A. Ide Gastric ulcer. , 2020, Minnesota medicine.

[2]  F. Chan,et al.  Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors , 2006, The American Journal of Gastroenterology.

[3]  G. Papatheodoridis,et al.  Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  J. Hippisley-Cox,et al.  Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis , 2005, BMJ : British Medical Journal.

[5]  C. Hawkey,et al.  Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin , 2005, Alimentary pharmacology & therapeutics.

[6]  Luis Rodrigo,et al.  A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use , 2005, The American Journal of Gastroenterology.

[7]  G. Thiéfin,et al.  Toxic effects of nonsteroidal antiinflammatory drugs on the small bowel, colon, and rectum. , 2005, Joint, bone, spine : revue du rhumatisme.

[8]  Claire Saadeh Chemotherapy‐ and Radiotherapy‐Induced Oral Mucositis: Review of Preventive Strategies and Treatment , 2005, Pharmacotherapy.

[9]  C. Hawkey,et al.  Nonsteroidal antiinflammatory drugs and the small intestine , 2005, Current opinion in gastroenterology.

[10]  R. Pwu,et al.  Risk estimates for drugs suspected of being associated with Stevens‐Johnson syndrome and toxic epidermal necrolysis: a case‐control study , 2005, Internal medicine journal.

[11]  B. Lewis,et al.  Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  V. Wong,et al.  Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. , 2005, The New England journal of medicine.

[13]  V. Wong,et al.  Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. , 2004, Gastroenterology.

[14]  J. Leighton,et al.  Diaphragm disease after use of nonsteroidal anti-inflammatory agents: first report of diagnosis with capsule endoscopy. , 2004, Journal of clinical gastroenterology.

[15]  F. Chan,et al.  Prevention of non‐steroidal anti‐inflammatory drug gastrointestinal complications – review and recommendations based on risk assessment , 2004, Alimentary pharmacology & therapeutics.

[16]  L. Biancone,et al.  Rofecoxib and early relapse of inflammatory bowel disease: an open‐label trial , 2004, Alimentary pharmacology & therapeutics.

[17]  A. Price Pathology of drug-associated gastrointestinal disease. , 2003, British journal of clinical pharmacology.

[18]  V. Lee,et al.  Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease , 2003, Alimentary pharmacology & therapeutics.

[19]  J. Avorn,et al.  The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. , 2003, The Journal of rheumatology.

[20]  T. Schnitzer,et al.  Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. , 2003, Gastroenterology.

[21]  F. Chan,et al.  Arthritis treatment in Hong Kong — cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents , 2002, Alimentary pharmacology & therapeutics.

[22]  R. Lindsay,et al.  Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. , 2002, Mayo Clinic proceedings.

[23]  A. Ottani,et al.  Dual acting anti-inflammatory drugs: a reappraisal. , 2001, Pharmacological research.

[24]  C. Funk,et al.  Prostaglandins and leukotrienes: advances in eicosanoid biology. , 2001, Science.

[25]  F. Chan,et al.  Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Approaching the end of the controversy in the new millennium, or room for more debate? , 2001, Journal of Gastroenterology.

[26]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[27]  L. Joseph,et al.  Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. , 2001, British journal of clinical pharmacology.

[28]  R. Fisher,et al.  Ischemic colitis during treatment with alosetron. , 2001, Gastroenterology.

[29]  C. Patrono Aspirin: new cardiovascular uses for an old drug. , 2001, The American journal of medicine.

[30]  Jacob,et al.  Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID‐enteropathy in the rat , 2000, Alimentary pharmacology & therapeutics.

[31]  P. Isakson,et al.  Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison , 1999, The Lancet.

[32]  I Larzillière,et al.  [Esophagitis associated with the use of alendronate]. , 1999, Gastroenterologie clinique et biologique.

[33]  M. Wolfe,et al.  Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.

[34]  Harp Jb Orlistat for the long-term treatment of obesity. , 1999 .

[35]  M. Gammon,et al.  Risk of esophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs, and other medications that promote gastroesophageal reflux. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  G. Singh,et al.  Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. , 1998, The American journal of medicine.

[37]  David Schultz,et al.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996, The Lancet.

[38]  M. Dennis A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[39]  G. Naylor,et al.  Oesophageal stricture associated with alendronic acid , 1996, The Lancet.

[40]  H T Hatoum,et al.  Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. , 1996, Archives of internal medicine.

[41]  H. Baillie-Johnson Octreotide in the management of treatment-related diarrhoea , 1996, Anti-Cancer Drugs.

[42]  A. Zinsmeister,et al.  Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly , 1995, Digestive Diseases and Sciences.

[43]  G. Weaver,et al.  Nonsteroidal antiinflammatory drugs are associated with gastric outlet obstruction. , 1995, Journal of clinical gastroenterology.

[44]  K. Davis Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[45]  N. Brousse,et al.  Drug induced lymphocytic colitis. , 1994, Gut.

[46]  A. Smyth,et al.  Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes , 1994, The Lancet.

[47]  R. Riddell,et al.  Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. , 1992, Gut.

[48]  A. Parker,et al.  Colonic strictures in a patient on long-term non-steroidal anti-inflammatory drugs. , 1992, Gastrointestinal endoscopy.

[49]  S. Sabanathan,et al.  Drug-induced esophagitis. , 1991, The American journal of gastroenterology.

[50]  M. W. Han,et al.  Ischemic colitis in a crack abuser , 1991, Digestive Diseases and Sciences.

[51]  D. Graham,et al.  Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. , 1987, The American journal of gastroenterology.

[52]  A. Blower,et al.  Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. , 1987, Gut.

[53]  H. Satoh,et al.  Role of bacteria in gastric ulceration produced by indomethacin in the rat: cytoprotective action of antibiotics. , 1983, Gastroenterology.

[54]  Y. Ishihara,et al.  Effects of cholestyramine and synthetic hydrotalcite on acute gastric or intestinal lesion formation in rats and dogs , 1981, Digestive Diseases and Sciences.

[55]  D. Rampton,et al.  Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. , 1981, Postgraduate medical journal.

[56]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[57]  D. Graham,et al.  Visible small-intestinal mucosal injury in chronic NSAID users. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[58]  J. Leichter,et al.  Drug-associated gingival enlargement: case report and review of aetiology, management and evidence-based outcomes of treatment. , 2005, Journal of the New Zealand Society of Periodontology.

[59]  P. Schoenfeld,et al.  Safety Profile of Tegaserod, a 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome , 2004, Drug safety.

[60]  A. Hui Encyclopedia of gastroenterology || gastric ulcer , 2004 .

[61]  James G. Anderson,et al.  A systems approach to preventing adverse drug events. , 2003, Studies in health technology and informatics.

[62]  F. Chan Helicobacter pylori and nonsteroidal anti-inflammatory drugs. , 2001, Gastroenterology clinics of North America.

[63]  K. Iwakiri,et al.  Effect of nifedipine administration (10 mg) on esophageal acid exposure time , 2000, Journal of Gastroenterology.

[64]  J. Harp Orlistat for the long-term treatment of obesity. , 1999, Drugs of today.

[65]  N. Davies,et al.  Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. , 1997, Gastroenterology.

[66]  D. Clement A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[67]  S. Syngal,et al.  Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. , 1995, Arthritis and rheumatism.

[68]  L. Knodel Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs , 1994 .

[69]  F. Halter,et al.  Diaphragm disease of the ascending colon. Association with sustained-release diclofenac. , 1993, Journal of clinical gastroenterology.

[70]  R. Haddock,et al.  Nabumetone. Evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans. , 1990, Drugs.